ITeos Therapeutics Tank 30% Impacted By Roche Holding Cancer Treatment Trial Failure

Shares of biotech company iTeos Therapeutics, Inc. (ITOS) are down 30 percent on Wednesday's trading. The stock was negatively impacted by news from pharma company Roche Holding AG (RHHBY) that an experimental immunotherapy tested in combination with the cancer treatment Tecentriq failed to meet the primary co-endpoint of progression-free survival in a Phase 3 clinical trial. The study was evaluating the combination therapy as a treatment for non-small cell lung cancer.

The news of the treatment failure had a negative impact on all the biotech stocks.

Currently at $17.81, the stock has traded between $16.95 and $52.93 during the past 52 weeks.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Biotech Investor.
Follow RTT